Latest KFF Health News Stories
States Step Up Push to Regulate Pharmacy Drug Brokers
In an ongoing effort to control prescription drug costs, states are targeting the companies that mediate deals among drug manufacturers, health insurers and pharmacies. The pharmacy benefit managers say they negotiate lower prices for patients, yet the nitty-gritty occurs largely behind a curtain that lawmakers are trying to pull back.
KHN’s ‘What the Health?’: How to Expand Health Coverage
Democrats in Congress and the states are devising strategies to expand health coverage — through the Affordable Care Act, Medicare, Medicaid and a “public option.” But progress remains halting, at best. Meanwhile, lawmakers in Washington may have to agree on how to control prescription drug prices if they wish to finance their coverage initiatives. Alice Miranda Ollstein of Politico, Tami Luhby of CNN and Shefali Luthra of The 19th join KHN’s Julie Rovner to discuss these issues and more. Also, Rovner interviews Michelle Andrews, who reported and wrote last month’s KHN-NPR “Bill of the Month” episode about a very expensive sleep study.
KHN’s ‘What the Health?’: The Drug Price Dilemma
Republicans, Democrats and the public at large agree that prices for prescription drugs are too high. But no one seems to know how to fix it. Vanderbilt University drug price researcher Stacie Dusetzina explains the basics of why drugs cost so much and why it’s hard to do something about it. Joanne Kenen of Politico, Sarah Karlin-Smith of the Pink Sheet and Anna Edney of Bloomberg News join KHN’s Julie Rovner to discuss the prospects for policy changes.
KHN Journalist Combs for Clues on Covid’s Origins
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.
Biden Administration Signals It’s in No Rush to Allow Canadian Drug Imports
Federal officials asked a court to dismiss a suit by drugmakers over the policy enacted by the Trump administration that would allow states to bring in cheaper prescription medications from Canada. The filing said the lawsuit was moot because it’s unclear when or if the FDA would approve any state’s importation plan.
Opioids Like ‘Lean’ Permeate Hip-Hop Culture, but Dangers Are Downplayed
In big cities and small towns, opioid use among some young hip-hop fans is about emulating their favorite rap star’s image — while paying little attention to the serious consequences.
Legisladores de Colorado se posicionan contra los altos costos de los medicamentos
Incapaz de fijar los precios o cambiar las protecciones de las patentes, el estado considera medidas legislativas y administrativas para reducir los gastos de bolsillo delos consumidores.
Colorado Lawmakers Wage Multifront Assault on High Drug Costs
Colorado is one of many states resolved not to wait for federal action to reduce drug costs. Its legislature is considering several ways to lower costs for consumers and the state.
KHN’s ‘What the Health?’: Drug Price Effort Hits a Snag
Democratic leaders in Congress have vowed to pass legislation to address high prescription drug prices this year, but some moderates in their own party appear to be balking. Meanwhile, younger teens are now eligible for a covid-19 vaccine and the Biden administration reinstated anti-discrimination policy for LGBTQ people in health care. Joanne Kenen of Politico, Sarah Karlin-Smith of the Pink Sheet and Rachel Cohrs of Stat join KHN’s Julie Rovner to discuss these issues and more.
Democrats Disagree About How to Spend Potential Prescription Drug Windfall
After a year of uncharacteristically being on the same page when it comes to health care, Democratic lawmakers are at loggerheads about what to do next. Most agree the time is ripe to tackle high drug prices. But they divide over whether to take savings from that to move to a ‘Medicare for All’ insurance system, enhance the current Medicare program or strengthen benefits under the Affordable Care Act.
KHN’s ‘What the Health?’: 100 Days of Health Policy
It’s 100 days into Joe Biden’s presidency and a surprisingly large number of health policies have been announced. But health is notably absent from the administration’s $1.8 trillion spending plan for American families, making it unclear how much more will get done this year. Meanwhile, the Centers for Disease Control and Prevention loosens its mask-wearing recommendations for those who have been vaccinated, but the new rules are confusing. Joanne Kenen of Politico, Mary Ellen McIntire of CQ Roll Call and Sarah Karlin-Smith of the Pink Sheet join KHN’s Julie Rovner to discuss these issues and more. Plus, Rovner interviews KHN’s Julie Appleby, who reported the latest KHN-NPR “Bill of the Month” episode.
Doctors More Likely to Prescribe Opioids to Covid ‘Long Haulers,’ Raising Addiction Fears
Chronic pain from covid can linger for months after patients appear to recover from the disease.
FDA Seeks a New Way to Review Old Drugs Without Causing Prices to Soar
A misguided federal program called the Unapproved Drugs Initiative, which put the FDA’s stamp of approval on old drugs, led to higher prices. It’s scrapped. So now what?
KHN’s ‘What the Health?’: Planning for Round Two
The ink is barely dry on the recent covid relief bill, but Democrats in Congress and President Joe Biden are wasting no time gearing up for their next big legislative package. Meanwhile, predictions of more states expanding Medicaid have proved premature. Alice Miranda Ollstein of Politico, Rachel Cohrs of Stat and Kimberly Leonard of Business Insider join KHN’s Julie Rovner to discuss these issues and more. Plus, Rovner interviews KHN’s Lauren Weber, who reported the latest KHN-NPR “Bill of the Month” episode.
Medicamentos ya conocidos, y baratos, podrían ser clave para tratar covid
Hay medicamentos aprobados hace años que podrían investigarse en profundidad para tratar covid. Pero no hay interés porque no generarían grandes ganancias.
Scientists Seek Covid Treatment Answers in Cheap, Older Drugs
Philanthropies are funding studies of cheap, existing medications like the antidepressant fluvoxamine as covid treatments. But early hype about hydroxychloroquine and other repurposed drugs leaves researchers leery of hasty conclusions.
How Much of Trump’s Health Agenda Has Biden Undone?
In his campaign, President Joe Biden promised to undo policies, particularly health policies, implemented by former President Donald Trump. Yet, despite immense executive power, reversing four years of action takes time and resources.
KHN’s ‘What the Health?’: Getting Down to Work at HHS
After a bruising confirmation process, Xavier Becerra was sworn in as secretary of Health and Human Services this week. The Senate also confirmed the nominations of former U.S. Surgeon General Vivek Murthy to return to the post he held in the Obama administration, and former Pennsylvania health secretary Rachel Levine as assistant secretary for health. Levine is the first openly transgender person to receive Senate confirmation. Meanwhile, questions continue to swirl around the AstraZeneca covid vaccine, which some public health experts worry will create more hesitancy toward other vaccines.
Democrats Eye Medicare Negotiations to Lower Drug Prices
Progressive and conservative Democratic lawmakers, as well as President Joe Biden, are in favor of authorizing federal officials to negotiate with drugmakers over what Medicare pays for at least some of the most expensive brand-name drugs and to base those prices on the drugs’ clinical benefits. Such a measure could put Republicans in the uncomfortable position of opposing an idea that most voters from both parties generally support.
As Drug Prices Keep Rising, State Lawmakers Propose Tough New Bills to Curb Them
The measures would impose taxes on increases in the price of drugs that don’t reflect improved clinical value and set the rates paid by state-run and commercial health plans to a benchmark based on prices in Canada.
